X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement with Alar, Indivior will secure exclusive global rights (except in China, Hong Kong, Taiwan and Macau) to develop, manufacture and commercialize ALA-1000 and Alar's future buprenorphine-based LAI product candidates.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: ALA-1000
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alar Pharmaceuticals
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 11, 2023
Details:
The collaboration aims for the discovery of novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates for the treatment of substance use disorder.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Addex Therapeutics
Deal Size: $335.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration August 02, 2023
Details:
Through the divestment, Indivior gains the proprietary rights to C4XD’s oral Orexin-1 receptor antagonist, INDV-2000 (C4X_3256) for substance use disorder.
Lead Product(s): C4X_3256
Therapeutic Area: Psychiatry/Psychology Product Name: INDV-2000
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: C4X Discovery
Deal Size: $20.4 million Upfront Cash: Undisclosed
Deal Type: Divestment August 01, 2023
Details:
Opvee (nalmefene) nasal spray is an opioid receptor antagonist approved by the Food and Drug Administration (FDA) to for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Opvee
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
Opvee (nalmefene) nasal spray is an opioid receptor antagonist approved by the Food and Drug Administration (FDA) to for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Opvee
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
The transaction strengthens Indivior's addiction treatment and science portfolio by adding Opiant's late-stage assets, notably OPNT003, a patented intranasal nalmefene formulation for opioid overdose treatment.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT003
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indivior
Deal Size: $213.0 million Upfront Cash: $145.0 million
Deal Type: Acquisition March 02, 2023
Details:
OPNT003 is a nasal formulation containing the high affinity opioid antagonist nalmefene. The NDA submission for OPNT003 is supported by results from a pharmacokinetic (PK) study comparing OPNT003 to an intramuscular nalmefene injection.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT003
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
As part of the amended agreement, Addex retains exclusive rights to develop its own independent gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) program.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Addex Therapeutics
Deal Size: $336.0 million Upfront Cash: $5.0 million
Deal Type: Expanded Collaboration December 08, 2022
Details:
OPNT003, an intranasal formulation of nalmefene, a more potent, longer acting opioid antagonist that is especially well-suited to treat overdose caused by synthetics, is an investigational treatment for opioid overdose.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT003
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
OPNT003 is an investigational opioid overdose reversal agent that Opiant has been developing alongside a worsening opioid crisis, driven by the increased prevalence of synthetic opioids, such as illicit fentanyl.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indivior
Deal Size: $213.0 million Upfront Cash: $145.0 million
Deal Type: Acquisition November 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
